Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $74.00

Posted by George Bondi on Aug 24th, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) had its target price lifted by Morgan Stanley from $67.00 to $74.00 in a research note released on Friday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the stock. Citigroup upped their price target on shares of Ultragenyx Pharmaceutical from $45.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday. Cantor Fitzgerald lifted their price objective on Ultragenyx Pharmaceutical from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Royal Bank Of Canada upped their target price on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Finally, Wedbush lowered their price target on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $58.89.

Get Our Latest Analysis on RARE

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $25.83 on Friday. The firm has a 50 day moving average of $28.58 and a 200-day moving average of $24.98. The firm has a market capitalization of $2.55 billion, a P/E ratio of -4.42 and a beta of 0.35. Ultragenyx Pharmaceutical has a 12 month low of $18.29 and a 12 month high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. During the same quarter in the prior year, the firm posted ($1.17) EPS. Ultragenyx Pharmaceutical’s revenue was up 28.5% on a year-over-year basis. Sell-side analysts predict that Ultragenyx Pharmaceutical will post -4.03 EPS for the current year.

Insider Activity

In related news, EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the sale, the executive vice president directly owned 94,462 shares in the company, valued at $2,325,654.44. This represents a 1.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the transaction, the director owned 21,095 shares in the company, valued at approximately $528,429.75. The trade was a 8.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 8,552 shares of company stock valued at $207,455. Insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in RARE. BlackRock Inc. bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $355,746,000. Assenagon Asset Management S.A. grew its stake in shares of Ultragenyx Pharmaceutical by 1,030.4% in the first quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock worth $47,298,000 after purchasing an additional 2,057,951 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in Ultragenyx Pharmaceutical by 614.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after purchasing an additional 1,864,164 shares during the last quarter. Norges Bank purchased a new stake in Ultragenyx Pharmaceutical in the fourth quarter worth $29,004,000. Finally, Bank of America Corp DE bought a new stake in Ultragenyx Pharmaceutical in the second quarter valued at $38,347,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

Positive Sentiment: The FDA granted accelerated approval to Genglycos (pariglasgene brecaparvovec), Ultragenyx’s gene therapy for glycogen storage disease type Ia (GSDIa). It is the first FDA-approved treatment designed to address the underlying cause of the rare metabolic disorder, potentially expanding the company’s commercial opportunity and strengthening its gene-therapy platform. Ultragenyx Announces FDA Approval of Genglycos
Positive Sentiment: Analysts raised their valuations following the approval. Cantor Fitzgerald increased its price target to $103 from $96 and maintained an “overweight” rating; Canaccord raised its target to $83 from $81 with a “buy” rating; Morgan Stanley lifted its target to $74 from $67 and maintained “overweight”; Citi raised its target to $58 from $45 with a “buy” rating; and Wells Fargo increased its target to $46 from $45 while retaining “overweight.” Ultragenyx FDA approval coverage
Positive Sentiment: Wells Fargo described the gene-therapy launch as a potential long-term revenue tailwind, suggesting Genglycos could create a more durable growth stream for RARE if adoption and reimbursement develop as expected. Wells Fargo Genglycos analysis
Neutral Sentiment: Despite the regulatory progress, investors still need evidence that Ultragenyx can convert approval into sustainable profitability. The company remains loss-making, making the pace of commercialization, revenue growth and cash generation important tests for the stock. Ultragenyx profitability analysis

Ultragenyx Pharmaceutical Company Profile

(Get Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.